Physician profile
Ramavathi Nandyala
NPI 1609837988
$7,782.86
in general payments reported to CMS, 2019-2025
40 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $590 · 2021: $1,518 · 2022: $936 · 2023: $1,549 · 2024: $1,220 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,974.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,380.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $800.32 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $775.01 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $539.60 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $511.80 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $416.10 | 2019-2025 | |
| Novo Nordisk INC | $411.53 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Boston Scientific Corporation | $408.15 | 2019-2025 | Watchman Flx, Watchman Access System |
| Sanofi-Aventis U.S. LLC | $287.95 | 2019-2024 | |
| Heartflow, INC. | $284.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $243.73 | 2020-2025 | Farxiga, Brilinta |
| Amgen INC. | $213.90 | 2019-2023 | Repatha |
| Scpharmaceuticals INC. | $173.05 | 2023-2025 | |
| Amarin Pharma, INC. | $138.13 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $122.17 | 2023-2024 | Inpefa |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramavathi Nandyala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.